Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Ashok Srivastava

Ashok Srivastava

Chief Medical Officer and CRO
Clinfomatrix
USA

Biography

Dr. Ashok Srivastava is Chief Executive Officer and Chief Medical Officer of Cure Pharmaceuticals, and ClinFomatrix Oncology CRO, He was founder, Chief Executive Officer and Chief Medical Officer of Care Beyond - A Radiation Therapy Cancer Center, New Jersey. USA. He has more than 15 years of experience in drug development, medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase 1 – 4, and marketing commercialization of Hematology, Oncology and radio-immuno-oncology drugs in USA, EU and Japan. He is leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials. He contributed to 21-INDs and 7-NDAs of Cancer Drugs, acquisition /merger of company and drug for more than $900 million. He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide at various executive leadership positions; Walter Reed Army Institute of Research and Medical Center, Daiichi Pharmaceuticals, Sumitomo Pharmaceuticals, Pharmacia, Pfizer, Eisai Oncology, Spectrum Pharmaceuticals and Taiho Oncology. He received his Clinical, Medical & Business educations from All India Institute of Medical Sciences, New Delhi, India; Academy of Medical Sciences, Czechoslovakia; School of Medicine Nagasaki University, Japan, and Pharmaceutical Business at Rutgers University Business Management, New Jersey, USA. He played key role in dramatic expansion of oncology drug – developed cancer drugs- Sutent (Sunitinib), Evoxac (Cevimeline HCl), and liposomal doxorubicin (Myocet) in combination with Herceptin & Paclitaxel for HER2 positive for metastatic breast cancer patients and Latuda (Lurasidone) for schizophrenia. He has published more than 85 papers in National and International Journals, more than 120 abstracts, 3 book chapters and 2 patents. He is recipient of numerous National & International prestigious medical awards and recognitions from United Nations, Ministry of Health, Japan, and Department of Army, Walter Reed Army Medical Center and Walter Reed Army Institute of Research, Washington DC, USA. He served as medical advisor to Poniard Pharmaceutical for small cell lung cancer and Taiho Oncology in USA, EU and India. Dr. Srivastava is member of numerous prestigious organizations; America’s Top Oncologist of the years 2017, Breast Cancer Foundation, Indian Society of Oncology, American Society of Clinical Oncology, American Society for Therapeutic Radiology & Oncology, American Association of Cancer Research, and International Society of Lung Cancer. Dr. Srivastava is a strategic medical advisor and Board Member to several pharma in USA for clinical, regulatory and supervises cancer drug development. Recently Dr. Srivastava was awarded membership of Japan External Trade Organization, USA. Dr. Srivastava is a Leader in Drug Safety, pharmacovigilance of Oncology, hematology, immuno-oncology and built global drug safety and pharmacovigilance companies in USA, and India. Dr. Srivastava was invited as an honorable speaker at drug safety & Pharmacovigilance congress in London, UK, India and Washington, DC, USA in 2017. Dr. Srivastava brought 2 cancer drugs & a vaccine in global market for approximately 3 – 3.5 billion $ in global sales. He serves as board of directors for oncology pharma companies in USA.

Research Interest

Global complex mega cancer drug trial & generic drugs drug development and medical affairs R&D & medical affairs; Phase I-IV and Life Cycle Management Chemotherapy, Immuno-oncology, Supportive Care Alliance Management/Joint Steering Committee Building High Performing Teams